Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$13.54 USD
-0.31 (-2.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $13.56 +0.02 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
URGN 13.54 -0.31(-2.24%)
Will URGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for URGN
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
Other News for URGN
Oppenheimer Remains a Buy on Urogen Pharma (URGN)
UroGen Pharma management to meet with Oppenheimer
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
UroGen Pharma receives new U.S. patent allowance for RTGel technology
UroGen Pharma management to meet with Oppenheimer